After an distinctive yr 2021 for enterprise capital funding within the US Biotech-sector, aggregated financing volumes in 2022 are for the primary time decrease than in 2021. Over the past months funding volumes have declined considerably.
Particularly in June, funding volumes have been virtually 3 times as excessive in contrast August.
Excluding the record-breaking Collection B financing of Altos Labs in January 2022 (USD 3,000m), this yr’s funding volumes would have already fallen behind in March on a year-to-year foundation.